Combretastatin A1 phosphate - Mateon Therapeutics

Drug Profile

Combretastatin A1 phosphate - Mateon Therapeutics

Alternative Names: CA1; CA1P; Combrestatin A1 diphosphate; Combretastatin A1 di-phosphate; OXi 4503

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics
  • Class Antineoplastics; Combretastatins; Diphosphates; Stilbenes
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Liver cancer; Liver metastases; Myelodysplastic syndromes
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in United Kingdom (IV, Infusion)
  • 03 Nov 2017 Adverse event and efficacy data from the a phase Ib/II trial in Acute myeloid leukaemia released by Mateon Therapeutics
  • 01 Aug 2017 Additional safety and efficacy data from a phase Ib trial in Acute myeloid leukaemia released by Mateon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top